JPMorgan Upgrades ADC Therapeutics (ADCT) to Neutral, 'fully valued'
Tweet Send to a Friend
(Updated - August 10, 2023 5:07 AM EDT)
JPMorgan analyst Brian Cheng upgraded ADC Therapeutics (NYSE: ADCT) from Underweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Brian Cheng upgraded ADC Therapeutics (NYSE: ADCT) from Underweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
